Pediatr. pro Praxi, 2002; 2: 58-61

RSV infekce - současné možnosti léčby a imunoprofylaxe

MUDr. Martin Čihař, MUDr. Karel Liška, MUDr. Klára Klenková
Novorozenecké oddělení s JIRP, Gynekologicko-porodnická klinika 2. LF UK a FN Motol, Praha

Keywords: respiratory syncytial virus (RSV), prematurity, treatment, prophylaxis.

Published: December 31, 2002  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čihař M, Liška K, Klenková K. RSV infekce - současné možnosti léčby a imunoprofylaxe. Pediatr. praxi. 2002;3(2):58-61.

Respiratory syncitial virus (RSV) je nejčastější příčinou bronchiolitid a pneumonií u dětí do 3 let věku. Předčasně narozené děti, děti s chronickým plicním onemocněním a děti s vrozenými srdečními vadami mají zvýšené riziko těžkého průběhu RSV infekce. Závažný je nejen akutní průběh onemocnění, ale i pozdní morbidita. Léčba je většinou pouze podpůrná a postupy jsou často kontroverzní. Imunoprofylaxe je v současné době optimálním přístupem.

RSV INFECTION - CURRENT THERAPY AND PREVENTION STRATEGIES

The respiratory syncytial virus (RSV) is the major cause of bronchiolitis and pneumonia in children up to the age of 3. Premature infants, infants with chronic lung disease and children with congenital heart disease are at a high risk of RSV infection. This infection not only manifests as a serious acute phase but also there is a high incidence of late morbidity. RSV treatment modalities are mainly supportive and often controversial, immunoprophylaxis being the optimal approach.

Novorozenecké oddělení s JIRP, Gynekologicko-porodnická klinika 2. LF UK a FN Motol, Praha

Neonatologické oddělení, Gynekologicko-porodnická klinika VFN a 1. LF UK, Praha

Download citation

References

  1. American Academy of Pediatrics. Prevention of respiratory syncytial virus infection: Indications for the use of Palivizumab and update on the use of RSV-IGIV. Pediatrics, 1998; 102: 1211-1216. Go to original source... Go to PubMed...
  2. Carbonell X, Guiffre L, Kimpen J, Adam D. Guidelines for the use of Synagis (Palivizumab), a humanized monoclonal antibody, for the prevention of respiratory syncytial virus (RSV) disease in high-risk infants: a consensus opinion. Infections in Medicine, 16, supplement G, 1999: 29-33.
  3. Collins PL, McIntosh K, Channock RM. Virology, Philadphia, Lippincot-Raven, 1996: 1313-1351.
  4. De Boeck K, Van de Aa N, Van Lierde S. Respiratory syncytial virus bronchiolitis: a double-blind dexamathasone efficacy study. J Pediatr 1997; 131: 919-921. Go to original source... Go to PubMed...
  5. Dobson JV, Stephens-Groff SM, McMahon SR. The use of albuterol in hospitalized infants with bronchiolitis. Pediatrics 1998; 101: 361-368. Go to original source... Go to PubMed...
  6. Grenough A. The impact of RSV disease, Expanding the horizons of pediatric RTI, September 2-3, 1999, Lisbon, Portugal.
  7. Hemming VG, Rodriguez W, Kim HW. Intravenous immunoglobulin treatment of respiratory syncytial virus infections in nfants and young childern. Antimicrob. Agents Chemother 1997; 31: 1882-1886. Go to original source... Go to PubMed...
  8. Johnson S, Oliver C, Prince GA. Developtment of humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997; 176: 1215-1224. Go to original source... Go to PubMed...
  9. Kapiakan AZ, Mitchell RH, Chanock RM. An epidemiological study of altered clinical reactivity to respiratory syncytial virus infection in childern previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969; 89: 405-421. Go to original source... Go to PubMed...
  10. Khan JY, Kerr SJ, Tometzki A. Role of ECMO in treatment of respiratory syncytial virus bronchiolitis: a collaborative report. Arch Dis Child 1995; 73: 91-94. Go to original source... Go to PubMed...
  11. Meert KL, Sarnaik AP, Gelmini MJ, et al. Aerosolized ribavirin in mechanically ventilated childern with respiratory syncytial virus lower respiratory tract disease: a prospective, double-blind randomized trial. Crit Care Med 1994; 22: 566-572. Go to original source... Go to PubMed...
  12. Moler FW, Sreinhart CM, Ohmit SE, et al. Effectiveness of ribavirin in othervise well infants with respiratory syncytial virus-associated respiratory frailure. J. Pediatr 1996; 128: 422-428. Go to original source... Go to PubMed...
  13. Murray M, Webb MS, Callagan C, et al. Respiratory status and allergy after bronchiolitis. Arch Dis Child 1992; 67: 482-487. Go to original source... Go to PubMed...
  14. Noble V, Murray M, Webb MS, et al. Respiratory status and allergy 9 to 10 years after acute bronchiolitis. Arch Dis Child 1997; 76: 315-319. Go to original source... Go to PubMed...
  15. Patel NR, Hammer J, Nichani S. Effect of inhaled nitric oxide on respiratory mechanics in ventilated infants with RSV bronchiolitis. Intensive Care Med 1999; 25: 81-87. Go to original source... Go to PubMed...
  16. Prevent Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997; 135: 546-548. Go to original source... Go to PubMed...
  17. Roosevelt G, Sheehan K, Grupp-Phelan J. Dexamethasone in bronchiolitis: a randomised controlled trial. Lancet 1996; 348: 292-295. Go to original source... Go to PubMed...
  18. Simoes EA. Respiratory syncytial virus infection. The Lancet, 1999; 354: 847-852. Go to original source... Go to PubMed...
  19. Simoes AE, Sondheimer HM, Top FH. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group, J Pediatr 1998; 133: 492-499. Go to original source... Go to PubMed...
  20. Ihe Impact Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus monoclonal antibody prophylaxis. Pediatrics, 1998; 102: 531-537. Go to original source...
  21. Top F. Clinical Overview of a Novel High-Tech, Monoclonal RSV Antibody. A Symposium on Novel Approaches in Prophylaxis of RSV, October 16, 1998; Paris.




Pediatrics for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.